PDCD1 and neoplasm: Vaccinated patients showed significantly delayed tumor recurrence and experienced complete tumor regression after anti-programmed cell death-1 (anti-PD-1) therapy, with the expansion of the repertoire of neoantigen-specific T cells [54,55,56].